“Pre-cebo”: An Unrecognized Issue in the Interpretation of Adequate Relief During Irritable Bowel Syndrome Drug Trials
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: In drug trials involving subjects with irritable bowel syndrome (IBS), the placebo effect seems to be very important. However, events even before starting the study may also impact patient expectations. In this study, we utilized consent language from prior studies of diarrhea predominant IBS (D-IBS) drug trials to determine whether the knowledge imparted during this process affects the response to different therapies. METHODS: Consecutive IBS subjects who met the Rome III criteria for IBS were enrolled. Patients were presented with a mock trial and randomized to 1 of 3 questionnaires with consent using similar language from consent forms of 3 drugs used in D-IBS: desipramine, alosetron, and rifaximin. Demographics, IBS symptoms using visual analog scale, and percent improvement needed for patients to report adequate relief of IBS from theoretically taking their assigned drug was asked. Data were expressed as mean ± SE. RESULTS: Subjects who were anticipating rifaximin had the highest expectation of improvement to determine adequate relief of 87.3 ± 10.9% compared with 73.4 ± 18.0% for desipramine (P<0.01) and 76.8 ± 20% for alosetron (P=0.049). There was no major difference in expectation of response from any medication to satisfy adequate relief on the basis of a belief that IBS is psychologic or organic in origin. In addition, sex and previous use of a drug did not influence the expectation of adequate relief. CONCLUSIONS: Benefits of drugs in D-IBS drug trials have the potential to be influenced by preconceived notions derived from familiarity of drug class and the consent process even before the study begins which we refer to as the "pre-cebo" effect. The higher pre-cebo effect for rifaximin may be an obstacle to successful treatment effect during drug trials compared with drugs such as desipramine. The pre-cebo effect may need to be taken into account when formulating consent forms for IBS study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationWhen words are painful: unraveling the mechanisms of the nocebo effect
Benedetti, F., Lanotte, M., Lopiano, L., & Colloca, L. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.02.020 · Cited by 636
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614
Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
Drossman, D. A., Patrick, D. L., Whitehead, W. E., Toner, B. B., Diamant, N. E., Hu, Y., Jia, H., & Bangdiwala, S. I. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01941.x · Cited by 424
Predictors of health care seeking for irritable bowel syndrome: a population based study
Talley, N. J., Boyce, P. M., & Jones, M. (1997) · Gut · doi:10.1136/gut.41.3.394 · Cited by 250
Gwee, K.-A., Wee, S., Wong, M.-L., & J C Png, D. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04161.x · Cited by 190
Cited by
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
“…(alosetron), or a local antibiotic (rifaximin), IBS patients expected the highest efficacy from treatments with which they were familiar (i.e., antibiotics), which the authors called a “pre-cebo” effect, i.e., preconceived notions from being familiar with the drug class (Kim et al., 2012).”
BackgroundPlacebo effects and their determinants in gastrointestinal disorders
Elsenbruch, S., & Enck, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.117 · Cited by 173
Placebo effects in psychotherapy: a framework
Enck, P., & Zipfel, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00456 · Cited by 115
Irritable bowel syndrome: a concise review of current treatment concepts
Wall, G. C., Bryant, G. A., Bottenberg, M. M., Maki, E. D., & Miesner, A. R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8796 · Cited by 56
Metadata
- Authors
- Kim, S. E., Kubomoto, S., Chua, K., Amichai, M. M., & Pimentel, M.
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2012-09
- Volume
- 46
- Issue
- 8
- Pages
- 686-690
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2330485749
- Cited by
- 14
- References
- 6
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: “Pre-cebo”: An Unrecognized Issue in the Interpretation of Adequate Relief During Irritable Bowel Syndrome Drug Trials. https://app.cochat.ai/papers/10.1097/mcg.0b013e31825828a7
- The paper
- Kim, S. E., Kubomoto, S., Chua, K., Amichai, M. M., & Pimentel, M. (2012). “Pre-cebo”: An Unrecognized Issue in the Interpretation of Adequate Relief During Irritable Bowel Syndrome Drug Trials. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e31825828a7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.